Anti-Human PD-L1 (CD274) (Clone 130021)

PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.

Purified No Carrier Protein

This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 6.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 6.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

Purified Recombinant Human CD274/PD-L1 (Accession # Q9NZQ7)

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

PD-L1